All In Biotech

Drug Trial Radar · NCT05126277

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multicenter Phase 3 Trial to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Participants With Active Lupus Nephritis (SIRIUS-LN).

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 452 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

452

Actual

Start

Jul 14, 2022

Primary completion

Sep 21, 2027

Study completion Feb 4, 2031

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN

Conditions

  • Lupus Nephritis

Interventions

  • ianalumab s.c. q4wDrug

    ianalumab s.c. q4w in addition to SoC

  • ianalumab s.c. q12wDrug

    ianalumab s.c. q12w in addition to SoC

  • placebo s.c.Drug

    placebo s.c. q4w in addition to SoC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and percentage of participants achieving stable Complete Renal Response (CRR)Time frame: Week 72

Locations

145 sites in 27 countries. Site status is shown where the registry gives one.

  • University Of Alabama

    Birmingham, Alabama

  • Advanced Medical Research

    La Palma, California

  • University of California Irvine

    Orange, California

  • School Of Medicine

    Sacromento, California

  • University of California San Diego

    San Deigo, California

  • Kaiser Permanente

    San Diego, California

  • Mayo Clinic Jacksonville

    Jacksonville, Florida

  • University Of Miami

    Miami, Florida

  • Emory University School of Medicine

    Atlanta, Georgia

  • Fides Clinical Research

    Atlanta, Georgia

  • Parris and Associates Rheumatology

    Lawrenceville, Georgia

  • Accurate Clinical Research

    Lake Charles, Louisiana

  • UMC New Orleans

    New Orleans, Louisiana

  • Wayne State University

    Detroit, Michigan

  • Univ of Nevada School of Med

    Las Vegas, Nevada

  • NY Nephrology

    Clifton Park, New York

  • Hospital for Special Surgery

    New York, New York

  • Northwell Health

    New York, New York

  • Circuit Clinical

    Orchard Park, New York

  • University Of Cincinnati

    Cincinnati, Ohio

  • Univ of Pennsylvania Medical Center

    Philadelphia, Pennsylvania

  • Precision Comprehensive Research

    Colleyville, Texas

  • Univof Texas Southwestern Med Cntr

    Dallas, Texas

  • Uni of Texas Health Science Center

    San Antonio, Texas

  • Uni Wisconsin School Med Pub Health

    Madison, Wisconsin

  • Novartis Investigative Site

    Caba, Argentina

  • Novartis Investigative Site

    CABA, Argentina

  • Novartis Investigative Site

    San Miguel de Tucumán, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    La Plata, Buenos Aires, Argentina

  • Novartis Investigative Site

    Salvador, Brazil

  • Novartis Investigative Site

    Vitória, Espírito Santo, Brazil

  • Novartis Investigative Site

    Salvador, Estado de Bahia, Brazil

  • Novartis Investigative Site

    Belo Horizonte, Minas Gerais, Brazil

  • Novartis Investigative Site

    Juiz de Fora, Minas Gerais, Brazil

  • Novartis Investigative Site

    Recife, Pernambuco, Brazil

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site

    Santo André, São Paulo, Brazil

  • Novartis Investigative Site

    Calgary, Alberta, Canada

Showing 40 of 145 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.